Metastatic Death Based on Presenting Features and Treatment for Advanced Intraocular Retinoblastoma: A Multicenter Registry-Based Study.

AJCC Advanced Chemotherapy Enucleation International Metastasis Multicenter Registry Retinoblastoma Staging

Journal

Ophthalmology
ISSN: 1549-4713
Titre abrégé: Ophthalmology
Pays: United States
ID NLM: 7802443

Informations de publication

Date de publication:
08 2022
Historique:
received: 19 03 2022
revised: 12 04 2022
accepted: 25 04 2022
pubmed: 3 5 2022
medline: 27 7 2022
entrez: 2 5 2022
Statut: ppublish

Résumé

To evaluate presenting features, tumor size, and treatment methods for risk of metastatic death due to advanced intraocular retinoblastoma (RB). International, multicenter, registry-based retrospective case series. A total of 1841 patients with advanced RB. Advanced RB was defined by 8th edition American Joint Committee on Cancer (AJCC) categories cT2 and cT3 and new AJCC-Ophthalmic Oncology Task Force (OOTF) Size Groups (1: < 50% of globe volume, 2: > 50% but < 2/3, 3: > 2/3, and 4: diffuse infiltrating RB). Treatments were primary enucleation, systemic chemotherapy with secondary enucleation, and systemic chemotherapy with eye salvage. Metastatic death. The 5-year Kaplan-Meier cumulative survival estimates by patient-level AJCC clinical subcategories were 98% for cT2a, 96% for cT2b, 88% for cT3a, 95% for cT3b, 92% for cT3c, 84% for cT3d, and 75% for cT3e RB. Survival estimates by treatment modality were 96% for primary enucleation, 89% for systemic chemotherapy and secondary enucleation, and 90% for systemic chemotherapy with eye salvage. Risk of metastatic mortality increased with increasing cT subcategory (P < 0.001). Cox proportional hazards regression analysis confirmed a higher risk of metastatic mortality in categories cT3c (glaucoma, hazard ratio [HR], 4.9; P = 0.011), cT3d (intraocular hemorrhage, HR, 14.0; P < 0.001), and cT3e (orbital cellulitis, HR, 19.6; P < 0.001) than in category cT2a and with systemic chemotherapy with secondary enucleation (HR, 3.3; P < 0.001) and eye salvage (HR, 4.9; P < 0.001) than with primary enucleation. The 5-year Kaplan-Meier cumulative survival estimates by AJCC-OOTF Size Groups 1 to 4 were 99%, 96%, 94%, and 83%, respectively. Mortality from metastatic RB increased with increasing Size Group (P < 0.001). Cox proportional hazards regression analysis revealed that patients with Size Group 3 (HR, 10.0; P = 0.002) and 4 (HR, 41.1; P < 0.001) had a greater risk of metastatic mortality than Size Group 1. The AJCC-RB cT2 and cT3 subcategories and size-based AJCC-OOTF Groups 3 (> 2/3 globe volume) and 4 (diffuse infiltrating RB) provided a robust stratification of clinical risk for metastatic death in advanced intraocular RB. Primary enucleation offered the highest survival rates for patients with advanced intraocular RB.

Identifiants

pubmed: 35500608
pii: S0161-6420(22)00310-4
doi: 10.1016/j.ophtha.2022.04.022
pmc: PMC9329221
mid: NIHMS1816535
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

933-945

Subventions

Organisme : NCI NIH HHS
ID : K08 CA232344
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Références

Ophthalmology. 2021 May;128(5):740-753
pubmed: 33007338
Br J Ophthalmol. 1960 Jan;44:35-41
pubmed: 14443414
Ophthalmology. 2003 Jan;110(1):13-4
pubmed: 12511339
Int J Ophthalmol. 2017 Jun 18;10(6):961-967
pubmed: 28730089
Pediatr Blood Cancer. 2012 Mar;58(3):356-61
pubmed: 21721113
Am J Ophthalmol. 2004 May;137(5):944-6
pubmed: 15126167
Eye (Lond). 2016 Jan;30(1):46-52
pubmed: 26427984
Int Ophthalmol Clin. 2019 Spring;59(2):77-86
pubmed: 30908281
Ophthalmology. 2015 Jun;122(6):1165-72
pubmed: 25841975
Lancet Glob Health. 2022 Mar;10(3):e307-e308
pubmed: 35093203
Pediatr Blood Cancer. 2008 Jan;50(1):160-2
pubmed: 17120241
Ophthalmology. 2020 Dec;127(12):1719-1732
pubmed: 32512116
Ophthalmology. 2006 Dec;113(12):2276-80
pubmed: 16996605
J Pediatr Hematol Oncol. 2009 May;31(5):325-9
pubmed: 19415010
Ophthalmol Retina. 2017 Jul - Aug;1(4):263-265
pubmed: 31047507
Cancers (Basel). 2021 Feb 08;13(4):
pubmed: 33567541
Prog Retin Eye Res. 2019 Nov;73:100764
pubmed: 31173880
Ophthalmol Clin North Am. 2005 Mar;18(1):41-53, viii
pubmed: 15763190
Surv Ophthalmol. 2002 Jan-Feb;47(1):1-16
pubmed: 11801265
JAMA Oncol. 2020 May 1;6(5):685-695
pubmed: 32105305
Ophthalmology. 2020 Dec;127(12):1733-1746
pubmed: 32526306
Ophthalmology. 2022 Aug;129(8):923-932
pubmed: 35436535
Acta Ophthalmol. 2020 Feb;98(1):e121-e125
pubmed: 31421017
Ophthalmology. 2019 Sep;126(9):1306-1314
pubmed: 30986443
Ocul Oncol Pathol. 2016 Apr;2(3):128-32
pubmed: 27239450

Auteurs

Ankit Singh Tomar (AS)

Department of Ocular Tumor, Orbital Disease, and Ophthalmic Radiation Therapy, The New York Eye Cancer Center, New York, New York.

Paul T Finger (PT)

Department of Ocular Tumor, Orbital Disease, and Ophthalmic Radiation Therapy, The New York Eye Cancer Center, New York, New York. Electronic address: pfinger@eyecancer.com.

Brenda Gallie (B)

The Eye Cancer Clinic, Princess Margaret Cancer Centre, and Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, Canada.

Tero T Kivelä (TT)

Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Ashwin Mallipatna (A)

The Eye Cancer Clinic, Princess Margaret Cancer Centre, and Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, Canada; Department of Ocular Oncology, Narayana Nethralaya Eye Hospital, Bangalore, India.

Chengyue Zhang (C)

Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China.

Junyang Zhao (J)

Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China.

Matthew W Wilson (MW)

Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, and Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.

Rachel C Brennan (RC)

Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, and Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.

Michala Burges (M)

Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, and Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.

Jonathan Kim (J)

USC Roski Eye Institute, Keck Medical School of the University of Southern California, Los Angeles, California; The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.

Jesse L Berry (JL)

USC Roski Eye Institute, Keck Medical School of the University of Southern California, Los Angeles, California; The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.

Rima Jubran (R)

USC Roski Eye Institute, Keck Medical School of the University of Southern California, Los Angeles, California; The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.

Vikas Khetan (V)

Department of Vitreoretina Services, Sankara Nethralaya, Chennai, Tamil Nadu, India.

Suganeswari Ganesan (S)

Department of Vitreoretina Services, Sankara Nethralaya, Chennai, Tamil Nadu, India.

Andrey Yarovoy (A)

Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation.

Vera Yarovaya (V)

Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation.

Elena Kotova (E)

Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation.

Denis Volodin (D)

Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation.

Yacoub A Yousef (YA)

Department of Surgery (Ophthalmology), King Hussein Cancer Center, Amman, Jordan.

Kalle Nummi (K)

Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Tatiana L Ushakova (TL)

SRI of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russian Federation; Medical Academy of Postgraduate Education, Moscow, Russian Federation.

Olga V Yugay (OV)

SRI of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russian Federation.

Vladimir G Polyakov (VG)

SRI of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russian Federation; Medical Academy of Postgraduate Education, Moscow, Russian Federation.

Marco A Ramirez-Ortiz (MA)

Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.

Elizabeth Esparza-Aguiar (E)

Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.

Guillermo Chantada (G)

Hemato-Oncology service, Hospital Sant Joan de Déu, Barcelona, Spain.

Paula Schaiquevich (P)

Precision Medicine Coordination Hospital JP Garrahan and CONICET, National Scientific and Technical Research Council, Buenos Aires, Argentina.

Adriana Fandino (A)

Ophthalmology Service Hospital JP Garrahan, Buenos Aires, Argentina.

Jason C Yam (JC)

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong.

Winnie W Lau (WW)

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong.

Carol P Lam (CP)

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong.

Phillipa Sharwood (P)

Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, University of Sydney, Sydney, Australia.

Sonia Moorthy (S)

KK Women's and Children's Hospital, Singapore.

Quah Boon Long (QB)

KK Women's and Children's Hospital, Singapore.

Vera Adobea Essuman (VA)

Ophthalmology Unit, Department of Surgery, University of Ghana Medical School, College of Health Sciences, University of Ghana, Accra, Ghana.

Lorna A Renner (LA)

Department of Child Health, University of Ghana Medical School, College of Health Sciences, University of Ghana, Accra, Ghana.

Ekaterina Semenova (E)

Department of Ocular Tumor, Orbital Disease, and Ophthalmic Radiation Therapy, The New York Eye Cancer Center, New York, New York.

Jaume Català-Mora (J)

Retinoblastoma Unit, Department of Ophthalmology, Hospital Sant Joan de Déu. Esplugues de Llobregat, Barcelona, Spain.

Genoveva Correa-Llano (G)

Retinoblastoma Unit, Department of Ophthalmology, Hospital Sant Joan de Déu. Esplugues de Llobregat, Barcelona, Spain.

Elisa Carreras (E)

Retinoblastoma Unit, Department of Ophthalmology, Hospital Sant Joan de Déu. Esplugues de Llobregat, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH